M Frumovitz1, M F Munsell2, J K Burzawa3, L A Byers4, P Ramalingam5, J Brown6, R L Coleman3. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mfrumovitz@mdanderson.org. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Gynecologic Oncology, Levine Cancer Institute, Charlotte, NC, USA.
Abstract
OBJECTIVES: To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. METHODS: We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. RESULTS: Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8months for TPB and 4.0months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P=0.001). Median overall survival (OS) was 9.7months for TPB and 9.4months for non-TPB regimens (HR 0.53, 95% CI 0.23-1.22, P=0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for >6months (P=0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for >12months (P=0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. CONCLUSIONS: These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.
OBJECTIVES: To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. METHODS: We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. RESULTS: Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8months for TPB and 4.0months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P=0.001). Median overall survival (OS) was 9.7months for TPB and 9.4months for non-TPB regimens (HR 0.53, 95% CI 0.23-1.22, P=0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for >6months (P=0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for >12months (P=0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. CONCLUSIONS: These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: William M Merritt; Christopher G Danes; Mian M K Shahzad; Yvonne G Lin; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Lingegowda S Mangala; Rebecca L Stone; Hye Sun Kim; David M Gershenson; Robert B Jaffe; Robert L Coleman; Joya Chandra; Anil K Sood Journal: Cancer Biol Ther Date: 2009-08-13 Impact factor: 4.742
Authors: Akila N Viswanathan; Michael T Deavers; Anuja Jhingran; Pedro T Ramirez; Charles Levenback; Patricia J Eifel Journal: Gynecol Oncol Date: 2004-04 Impact factor: 5.482
Authors: Michael Frumovitz; Jennifer K Burzawa; Lauren A Byers; Yasmin A Lyons; Preetha Ramalingam; Robert L Coleman; Jubilee Brown Journal: Gynecol Oncol Date: 2016-04-15 Impact factor: 5.482
Authors: Kathryn Kostamo; Mishka Peart; Nathalie McKenzie; Conisha Holloman; S J Carlan; Li Ge; John Maksem Journal: Case Rep Oncol Med Date: 2018-02-04
Authors: Mohammad Hassan Hodroj; Achraf Jardaly; Sarah Abi Raad; Annalise Zouein; Sandra Rizk Journal: Cancer Manag Res Date: 2018-05-10 Impact factor: 3.989
Authors: Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek Journal: BMC Cancer Date: 2018-05-04 Impact factor: 4.430
Authors: R Tyler Hillman; Robert Cardnell; Junya Fujimoto; Won-Chul Lee; Jianjun Zhang; Lauren A Byers; Preetha Ramalingam; Mario Leitao; Elizabeth Swisher; P Andrew Futreal; Michael Frumovitz Journal: PLoS One Date: 2020-06-16 Impact factor: 3.240